Activity
| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
27 actions
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.10 | ELOVL5 |
Ida Ertmanska changed review comment from: PMID: 40940404 Watanabe et al., 2025 Patient 3 - Japanese male, het for ELOVL5 c.179 C > T, p.S60F variant. This variant has 2 alleles reported in gnomAD v4.1.1, no homozygotes. Patient exhibited slowly progressive SCA with dysarthria, limb ataxia, and truncal ataxia, but no spasticity. Disease onset was at 37 years old; he became wheelchair dependent at 53 yrs. Brain stem and cerebellar atrophy noted. He had an additional feature of bladder and rectal disturbances. Family history: Mother, sibling, maternal uncle, and maternal aunt affected. No family genetic testing done. PMID: 32314013 Gazulla et al., 2020 Family with 5 affected individuals with gait ataxia and intermittent diplopia. Vestibular impairment and sensory neuronopathy were also noted. WES demonstrated a heterozygous variant in ELOVL5, c.779A>G (p.Tyr260Cys), in four tested patients. Disease onset was during 5th and 6th decades. Variant is LIKELY BENIGN in ClinVar, reported in gnomAD v4.1.1 with MAF = 0.001286 (European Non-Finnish population), including 1 homozygote - way too common for a dominant disease. PMID: 25065913 DiGregorio et al., 2014 Three SCA-affected Italian families (2 have confirmed shared ancestry, third may be more distantly related or same variant arose spontaneously). ELOVL5 heterozygous variant c.689G>T, p.Gly230Val cosegregated with disease. Variant is not present in gnomAD v4.1.1. Disease onset was around 34-45 years of age, with slowly progressive symptoms. Another heterozygous missense variant, ELOVL5 c.214C>G, p.Leu72Val, was detected in a French family with SCA. Variant is reported in 1 heterozygote in gnomAD v4.1.1. The female proband had ataxia with age of onset 51 years. FUNCTIONAL EVIDENCE: PMID: 37199746 Ferrero et al., 2023 - same research group as PMID: 25065913 Functional evidence showing that ELOVL5 c.689G>T p.Gly230Val is proteotoxic - mouse cortical neurons were transduced with lentiviruses expressing GFP and an ELOVL5 protein (wild type or mutant). Wild-type ELOVL5 did not affect neuronal viability whereas expression of p.G230V decreased neuronal viability by 10%. ; to: PMID: 40940404 Watanabe et al., 2025 Patient 3 - Japanese male, het for ELOVL5 c.179 C > T, p.S60F variant. This variant has 2 alleles reported in gnomAD v4.1.1, no homozygotes. Patient exhibited slowly progressive SCA with dysarthria, limb ataxia, and truncal ataxia, but no spasticity. Disease onset was at 37 years old; he became wheelchair dependent at 53 yrs. Brain stem and cerebellar atrophy noted. He had an additional feature of bladder and rectal disturbances. Family history: Mother, sibling, maternal uncle, and maternal aunt affected. No family genetic testing done. PMID: 32314013 Gazulla et al., 2020 Family with 5 affected individuals with gait ataxia and intermittent diplopia. Vestibular impairment and sensory neuronopathy were also noted. WES demonstrated a heterozygous variant in ELOVL5, c.779A>G (p.Tyr260Cys), in four tested patients. Disease onset was during 5th and 6th decades. Variant is LIKELY BENIGN in ClinVar, reported in gnomAD v4.1.1 with MAF = 0.001286 (European Non-Finnish population), including 1 homozygote - way too common for a dominant disease. PMID: 25065913 DiGregorio et al., 2014 Three SCA-affected Italian families (2 have confirmed shared ancestry, third may be more distantly related or same variant arose spontaneously). ELOVL5 heterozygous variant c.689G>T, p.Gly230Val cosegregated with disease. Variant is not present in gnomAD v4.1.1. Disease onset was around 34-45 years of age, with slowly progressive symptoms. Another heterozygous missense variant, ELOVL5 c.214C>G, p.Leu72Val, was detected in a French family with SCA. Variant is reported in 1 heterozygote in gnomAD v4.1.1. The female proband had ataxia with age of onset 51 years. FUNCTIONAL EVIDENCE: PMID: 37199746 Ferrero et al., 2023 - same research group as PMID: 25065913 Functional evidence showing that ELOVL5 c.689G>T p.Gly230Val is proteotoxic - mouse cortical neurons were transduced with lentiviruses expressing GFP and an ELOVL5 protein (wild type or mutant). Wild-type ELOVL5 did not affect neuronal viability whereas expression of p.G230V decreased neuronal viability by 10%. This gene is associated with AD Spinocerebellar ataxia 38, MIM:615957 (OMIM accessed 14th Aug 2026). |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.10 | ELOVL5 | Ida Ertmanska Phenotypes for gene: ELOVL5 were changed from Spinocerebellar ataxia 38, 615957; Spinocerebellar ataxia 36 615957 to Spinocerebellar ataxia 38, OMIM:615957; spinocerebellar ataxia type 38, MONDO:0014417 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.9 | ELOVL5 | Ida Ertmanska Publications for gene: ELOVL5 were set to | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.8 | ELOVL5 | Ida Ertmanska Mode of inheritance for gene: ELOVL5 was changed from MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown to MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.7 | ELOVL5 | Ida Ertmanska Mode of pathogenicity for gene: ELOVL5 was changed from Other - please provide details in the comments to Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype - please provide details in the comments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.6 | ELOVL5 | Ida Ertmanska Classified gene: ELOVL5 as Amber List (moderate evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.6 | ELOVL5 | Ida Ertmanska Added comment: Comment on list classification: There are now 3 unrelated families reported in literature with 3 unique monoallelic ELOVL5 missense variants, affected by adult-onset spinocerebellar ataxia. There is also a fourth pedigree, reported in PMID: 32314013, with a likely benign variant with a high allele frequency in gnomAD (not counted). Based on available evidence, this gene can be promoted to Green at the next update. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.6 | ELOVL5 | Ida Ertmanska Gene: elovl5 has been classified as Amber List (Moderate Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.5 | ELOVL5 | Ida Ertmanska Tag Q3_26_promote_green tag was added to gene: ELOVL5. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.5 | ELOVL5 |
Ida Ertmanska changed review comment from: PMID: 40940404 Watanabe et al., 2025 Patient 3 - Japanese male, het for ELOVL5 c.179 C > T, p.S60F variant. This variant has 2 alleles reported in gnomAD v4.1.1, no homozygotes. Patient exhibited slowly progressive SCA with dysarthria, limb ataxia, and truncal ataxia, but no spasticity. Disease onset was at 37 years old; he became wheelchair dependent at 53 yrs. Brain stem and cerebellar atrophy noted. He had an additional feature of bladder and rectal disturbances. Family history: Mother, sibling, maternal uncle, and maternal aunt affected. No family genetic testing done. PMID: 32314013 Gazulla et al., 2020 Family with 5 affected individuals with gait ataxia and intermittent diplopia. Vestibular impairment and sensory neuronopathy were also noted. WES demonstrated a heterozygous variant in ELOVL5, c.779A>G (p.Tyr260Cys), in four tested patients. Disease onset was during 5th and 6th decades. Variant is LIKELY BENIGN in ClinVar, reported in gnomAD v4.1.1 with MAF = 0.001286 (European Non-Finnish population), including 1 homozygote - way too common for a dominant disease. PMID: 25065913 DiGregorio et al., 2014 SCA-affected Italian family. ELOVL5 heterozygous variant c.689G>T, p.Gly230Val cosegregated with disease. Variant is not present in gnomAD v4.1.1. Another heterozygous missense variant, ELOVL5 c.214C>G, p.Leu72Val, was detected in a French family with SCA. Variant is reported in 1 heterozygote in gnomAD v4.1.1. FUNCTIONAL EVIDENCE: PMID: 37199746 Ferrero et al., 2023 - same research group as PMID: 25065913 Functional evidence showing that ELOVL5 c.689G>T p.Gly230Val is proteotoxic - mouse cortical neurons were transduced with lentiviruses expressing GFP and an ELOVL5 protein (wild type or mutant). Wild-type ELOVL5 did not affect neuronal viability whereas expression of p.G230V decreased neuronal viability by 10%.; to: PMID: 40940404 Watanabe et al., 2025 Patient 3 - Japanese male, het for ELOVL5 c.179 C > T, p.S60F variant. This variant has 2 alleles reported in gnomAD v4.1.1, no homozygotes. Patient exhibited slowly progressive SCA with dysarthria, limb ataxia, and truncal ataxia, but no spasticity. Disease onset was at 37 years old; he became wheelchair dependent at 53 yrs. Brain stem and cerebellar atrophy noted. He had an additional feature of bladder and rectal disturbances. Family history: Mother, sibling, maternal uncle, and maternal aunt affected. No family genetic testing done. PMID: 32314013 Gazulla et al., 2020 Family with 5 affected individuals with gait ataxia and intermittent diplopia. Vestibular impairment and sensory neuronopathy were also noted. WES demonstrated a heterozygous variant in ELOVL5, c.779A>G (p.Tyr260Cys), in four tested patients. Disease onset was during 5th and 6th decades. Variant is LIKELY BENIGN in ClinVar, reported in gnomAD v4.1.1 with MAF = 0.001286 (European Non-Finnish population), including 1 homozygote - way too common for a dominant disease. PMID: 25065913 DiGregorio et al., 2014 Three SCA-affected Italian families (2 have confirmed shared ancestry, third may be more distantly related or same variant arose spontaneously). ELOVL5 heterozygous variant c.689G>T, p.Gly230Val cosegregated with disease. Variant is not present in gnomAD v4.1.1. Disease onset was around 34-45 years of age, with slowly progressive symptoms. Another heterozygous missense variant, ELOVL5 c.214C>G, p.Leu72Val, was detected in a French family with SCA. Variant is reported in 1 heterozygote in gnomAD v4.1.1. The female proband had ataxia with age of onset 51 years. FUNCTIONAL EVIDENCE: PMID: 37199746 Ferrero et al., 2023 - same research group as PMID: 25065913 Functional evidence showing that ELOVL5 c.689G>T p.Gly230Val is proteotoxic - mouse cortical neurons were transduced with lentiviruses expressing GFP and an ELOVL5 protein (wild type or mutant). Wild-type ELOVL5 did not affect neuronal viability whereas expression of p.G230V decreased neuronal viability by 10%. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.5 | ELOVL5 |
Ida Ertmanska changed review comment from: PMID: 40940404 Watanabe et al., 2025 Patient 3 - Japanese male, het for ELOVL5 c.179 C > T, p.S60F variant. Patient exhibited slowly progressive SCA with dysarthria, limb ataxia, and truncal ataxia, but no spasticity. Disease onset was at 37 years old; he became wheelchair dependent at 53 yrs. Brain stem and cerebellar atrophy noted. He had an additional feature of bladder and rectal disturbances. Family history: Mother, sibling, maternal uncle, and maternal aunt affected. No family genetic testing done. PMID: 32314013 Gazulla et al., 2020 Family with 5 affected individuals with gait ataxia and intermittent diplopia. Vestibular impairment and sensory neuronopathy were also noted. WES demonstrated a heterozygous variant in ELOVL5, c.779A>G (p.Tyr260Cys), in four tested patients. Disease onset was during 5th and 6th decades. Variant is LIKELY BENIGN in ClinVar, reported in gnomAD v4.1.1 with MAF = 0.001286 (European Non-Finnish population), including 1 homozygote. PMID: 25065913 DiGregorio et al., 2014 SCA-affected Italian family. ELOVL5 heterozygous variant c.689G>T, p.Gly230Val cosegregated with disease. Variant is not present in gnomAD v4.1.1. Another heterozygous missense variant, ELOVL5 c.214C>G, p.Leu72Val, was detected in a French family with SCA. Variant is reported in 1 heterozygote in gnomAD v4.1.1. FUNCTIONAL EVIDENCE: PMID: 37199746 Ferrero et al., 2023 - same research group as PMID: 25065913 Functional evidence showing that ELOVL5 c.689G>T p.Gly230Val is proteotoxic - mouse cortical neurons were transduced with lentiviruses expressing GFP and an ELOVL5 protein (wild type or mutant). Wild-type ELOVL5 did not affect neuronal viability whereas expression of p.G230V decreased neuronal viability by 10%.; to: PMID: 40940404 Watanabe et al., 2025 Patient 3 - Japanese male, het for ELOVL5 c.179 C > T, p.S60F variant. This variant has 2 alleles reported in gnomAD v4.1.1, no homozygotes. Patient exhibited slowly progressive SCA with dysarthria, limb ataxia, and truncal ataxia, but no spasticity. Disease onset was at 37 years old; he became wheelchair dependent at 53 yrs. Brain stem and cerebellar atrophy noted. He had an additional feature of bladder and rectal disturbances. Family history: Mother, sibling, maternal uncle, and maternal aunt affected. No family genetic testing done. PMID: 32314013 Gazulla et al., 2020 Family with 5 affected individuals with gait ataxia and intermittent diplopia. Vestibular impairment and sensory neuronopathy were also noted. WES demonstrated a heterozygous variant in ELOVL5, c.779A>G (p.Tyr260Cys), in four tested patients. Disease onset was during 5th and 6th decades. Variant is LIKELY BENIGN in ClinVar, reported in gnomAD v4.1.1 with MAF = 0.001286 (European Non-Finnish population), including 1 homozygote - way too common for a dominant disease. PMID: 25065913 DiGregorio et al., 2014 SCA-affected Italian family. ELOVL5 heterozygous variant c.689G>T, p.Gly230Val cosegregated with disease. Variant is not present in gnomAD v4.1.1. Another heterozygous missense variant, ELOVL5 c.214C>G, p.Leu72Val, was detected in a French family with SCA. Variant is reported in 1 heterozygote in gnomAD v4.1.1. FUNCTIONAL EVIDENCE: PMID: 37199746 Ferrero et al., 2023 - same research group as PMID: 25065913 Functional evidence showing that ELOVL5 c.689G>T p.Gly230Val is proteotoxic - mouse cortical neurons were transduced with lentiviruses expressing GFP and an ELOVL5 protein (wild type or mutant). Wild-type ELOVL5 did not affect neuronal viability whereas expression of p.G230V decreased neuronal viability by 10%. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.5 | ELOVL5 | Ida Ertmanska edited their review of gene: ELOVL5: Changed publications to: 25065913, 32314013, 37199746, 40940404 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.5 | ELOVL5 |
Ida Ertmanska changed review comment from: PMID: 40940404 Watanabe et al., 2025 Patient 3 - Japanese male, het for ELOVL5 c.179 C > T, p.S60F variant. Patient exhibited slowly progressive SCA with dysarthria, limb ataxia, and truncal ataxia, but no spasticity. Disease onset was at 37 years old; he became wheelchair dependent at 53 yrs. Brain stem and cerebellar atrophy noted. He had an additional feature of bladder and rectal disturbances. Family history: Mother, sibling, maternal uncle, and maternal aunt affected.; to: PMID: 40940404 Watanabe et al., 2025 Patient 3 - Japanese male, het for ELOVL5 c.179 C > T, p.S60F variant. Patient exhibited slowly progressive SCA with dysarthria, limb ataxia, and truncal ataxia, but no spasticity. Disease onset was at 37 years old; he became wheelchair dependent at 53 yrs. Brain stem and cerebellar atrophy noted. He had an additional feature of bladder and rectal disturbances. Family history: Mother, sibling, maternal uncle, and maternal aunt affected. No family genetic testing done. PMID: 32314013 Gazulla et al., 2020 Family with 5 affected individuals with gait ataxia and intermittent diplopia. Vestibular impairment and sensory neuronopathy were also noted. WES demonstrated a heterozygous variant in ELOVL5, c.779A>G (p.Tyr260Cys), in four tested patients. Disease onset was during 5th and 6th decades. Variant is LIKELY BENIGN in ClinVar, reported in gnomAD v4.1.1 with MAF = 0.001286 (European Non-Finnish population), including 1 homozygote. PMID: 25065913 DiGregorio et al., 2014 SCA-affected Italian family. ELOVL5 heterozygous variant c.689G>T, p.Gly230Val cosegregated with disease. Variant is not present in gnomAD v4.1.1. Another heterozygous missense variant, ELOVL5 c.214C>G, p.Leu72Val, was detected in a French family with SCA. Variant is reported in 1 heterozygote in gnomAD v4.1.1. FUNCTIONAL EVIDENCE: PMID: 37199746 Ferrero et al., 2023 - same research group as PMID: 25065913 Functional evidence showing that ELOVL5 c.689G>T p.Gly230Val is proteotoxic - mouse cortical neurons were transduced with lentiviruses expressing GFP and an ELOVL5 protein (wild type or mutant). Wild-type ELOVL5 did not affect neuronal viability whereas expression of p.G230V decreased neuronal viability by 10%. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v9.5 | ELOVL5 | Ida Ertmanska reviewed gene: ELOVL5: Rating: GREEN; Mode of pathogenicity: None; Publications: 40940404; Phenotypes: Spinocerebellar ataxia 38, OMIM:615957, spinocerebellar ataxia type 38, MONDO:0014417; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.188 | ELOVL5 | Louise Daugherty commented on gene: ELOVL5: Downgraded rating from Green to Amber. As discussed with the GMS Neurology Specialist Test Group webex call 26th July 2019: The Specialist Test Group all agreed that there is only enough evidence to rate this gene Amber | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.187 | ELOVL5 |
Louise Daugherty Source Expert Review Amber was added to ELOVL5. Rating Changed from Green List (high evidence) to Amber List (moderate evidence) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.16 | ELOVL5 | Louise Daugherty Classified gene: ELOVL5 as Green List (high evidence) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.16 | ELOVL5 | Louise Daugherty Gene: elovl5 has been classified as Green List (High Evidence). | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.14 | ELOVL5 | Louise Daugherty commented on gene: ELOVL5: Review and rating submitted byJames Polke (North Bristol NHS Trust), on behalf of London North GLH for GMS Neurology specialist test group | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.13 | ELOVL5 | Louise Daugherty Source London North GMS was added to ELOVL5. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.11 | ELOVL5 | James Polke reviewed gene: ELOVL5: Rating: RED; Mode of pathogenicity: ; Publications: ; Phenotypes: ; Mode of inheritance: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.9 | ELOVL5 | Louise Daugherty Added phenotypes Spinocerebellar ataxia 38, 615957 for gene: ELOVL5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.8 | ELOVL5 | Louise Daugherty reviewed gene: ELOVL5: Rating: AMBER; Mode of pathogenicity: ; Publications: ; Phenotypes: ; Mode of inheritance: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.7 | ELOVL5 | Tracy Lester reviewed gene: ELOVL5: Rating: GREEN; Mode of pathogenicity: Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype -please provide details in the comments; Publications: ; Phenotypes: Spinocerebellar ataxia 38, 615957; Mode of inheritance: MONOALLELIC, autosomal or pseudoautosomal, NOT imprinted; Current diagnostic: yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.2 | ELOVL5 | Louise Daugherty Source NHS GMS was added to ELOVL5. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v1.1 | ELOVL5 | Louise Daugherty Source Wessex and West Midlands GLH was added to ELOVL5. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Hereditary ataxia, adult onset v0.2 | ELOVL5 |
Eleanor Williams gene: ELOVL5 was added gene: ELOVL5 was added to Hereditary ataxia - adult onset. Sources: Hereditary ataxia v1.148,Expert Review Red Mode of inheritance for gene: ELOVL5 was set to MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknown Phenotypes for gene: ELOVL5 were set to Spinocerebellar ataxia 36 615957 Mode of pathogenicity for gene: ELOVL5 was set to Other - please provide details in the comments |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||